Cardiorenal syndrome in thalassemia patients.
Adolescent
Adult
Blood Transfusion
Cardio-Renal Syndrome
/ blood
Female
Hematopoiesis, Extramedullary
Humans
Hypertension, Pulmonary
/ epidemiology
Iron Chelating Agents
/ therapeutic use
Male
Middle Aged
Natriuretic Peptide, Brain
/ blood
Peptide Fragments
/ blood
Young Adult
alpha-Thalassemia
/ blood
beta-Thalassemia
/ blood
Cardiorenal syndrome
Heart failure
Kidney failure
Thalassemia
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
03 08 2020
03 08 2020
Historique:
received:
04
02
2020
accepted:
29
07
2020
entrez:
5
8
2020
pubmed:
5
8
2020
medline:
21
10
2021
Statut:
epublish
Résumé
Cardiorenal syndrome (CRS), a serious condition with high morbidity and mortality, is characterized by the coexistence of cardiac abnormality and renal dysfunction. There is limited information about CRS in association thalassemia. This study aimed to investigate the prevalence of CRS in thalassemia patients and also associated risk factors. Thalassemia patients who attended the out-patient clinic of a tertiary care university hospital from October 2016 to September 2017 were enrolled onto this cross-sectional study. Clinical and laboratory findings from 2 consecutive visits, 3 months apart, were assessed. The criteria for diagnosis of CRS was based on a system proposed by Ronco and McCullough. Cardiac abnormalities are assessed by clinical presentation, establishment of acute or chronic heart failure using definitions from 2016 ESC guidelines or from structural abnormalities shown in an echocardiogram. Renal dysfunction was defined as chronic kidney disease according to the 2012 KDIGO guidelines. Out of 90 thalassemia patients, 25 (27.8%) had CRS. The multivariable analysis showed a significant association between CRS and extramedullary hematopoiesis (EMH) (odds ratio (OR) 20.55, p = 0.016); thalassemia type [β CRS is relatively common in thalassemia patients. Its occurrence is associated with laboratory parameters which are easily measured in clinical practice.
Sections du résumé
BACKGROUND
Cardiorenal syndrome (CRS), a serious condition with high morbidity and mortality, is characterized by the coexistence of cardiac abnormality and renal dysfunction. There is limited information about CRS in association thalassemia. This study aimed to investigate the prevalence of CRS in thalassemia patients and also associated risk factors.
METHODS
Thalassemia patients who attended the out-patient clinic of a tertiary care university hospital from October 2016 to September 2017 were enrolled onto this cross-sectional study. Clinical and laboratory findings from 2 consecutive visits, 3 months apart, were assessed. The criteria for diagnosis of CRS was based on a system proposed by Ronco and McCullough. Cardiac abnormalities are assessed by clinical presentation, establishment of acute or chronic heart failure using definitions from 2016 ESC guidelines or from structural abnormalities shown in an echocardiogram. Renal dysfunction was defined as chronic kidney disease according to the 2012 KDIGO guidelines.
RESULTS
Out of 90 thalassemia patients, 25 (27.8%) had CRS. The multivariable analysis showed a significant association between CRS and extramedullary hematopoiesis (EMH) (odds ratio (OR) 20.55, p = 0.016); thalassemia type [β
CONCLUSIONS
CRS is relatively common in thalassemia patients. Its occurrence is associated with laboratory parameters which are easily measured in clinical practice.
Identifiants
pubmed: 32746879
doi: 10.1186/s12882-020-01990-8
pii: 10.1186/s12882-020-01990-8
pmc: PMC7398251
doi:
Substances chimiques
Iron Chelating Agents
0
Peptide Fragments
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
325Subventions
Organisme : Faculty of Medicine, Chiang Mai University
ID : MED 046/2017
Pays : International
Références
Am J Kidney Dis. 2009 Dec;54(6):1012-24
pubmed: 19850388
Hematology Am Soc Hematol Educ Program. 2004;:14-34
pubmed: 15561674
Int J Nephrol Renovasc Dis. 2015 Oct 15;8:139-44
pubmed: 26508883
J Card Fail. 2019 Aug;25(8):654-665
pubmed: 31128242
Ren Fail. 2015 Jun;37(5):772-6
pubmed: 25869054
Eur J Heart Fail. 2007 May;9(5):531-6
pubmed: 17317307
Clin Exp Nephrol. 2018 Apr;22(2):486-487
pubmed: 28913562
Ital J Pediatr. 2010 May 25;36:39
pubmed: 20500848
Genet Med. 2010 Feb;12(2):61-76
pubmed: 20098328
Mediterr J Hematol Infect Dis. 2014 Sep 01;6(1):e2014057
pubmed: 25237470
Clin Biochem. 2010 Apr;43(6):615-20
pubmed: 20026020
Iran Red Crescent Med J. 2015 Jan 17;17(1):e18242
pubmed: 25763274
Rev Cardiovasc Med. 2004 Winter;5(1):16-25
pubmed: 15029111
Br J Haematol. 2011 Apr;153(1):111-7
pubmed: 21332704
Acta Haematol. 2010;123(3):148-52
pubmed: 20185899
Indian J Med Res. 2011 Oct;134:498-506
pubmed: 22089614
Clin J Am Soc Nephrol. 2009 Feb;4(2):337-44
pubmed: 19176795
Eur Heart J. 2010 Mar;31(6):703-11
pubmed: 20037146
Korean J Lab Med. 2011 Apr;31(2):72-80
pubmed: 21474979
Eur J Heart Fail. 2020 Feb;22(2):251-263
pubmed: 31863682
Blood. 2001 Jun 1;97(11):3411-6
pubmed: 11369631
Clin Chem Lab Med. 2015 Jan;53(1):73-83
pubmed: 25153411
Haematologica. 2004 Oct;89(10):1187-93
pubmed: 15477202
Saudi J Kidney Dis Transpl. 2011 May;22(3):497-500
pubmed: 21566307
Am J Clin Nutr. 1983 Mar;37(3):478-94
pubmed: 6829490
Cardiovasc Hematol Agents Med Chem. 2012 Mar 1;10(1):25-30
pubmed: 22239492
Am J Kidney Dis. 2015 Feb;65(2):177-205
pubmed: 25511161
Eur J Haematol. 2012 Sep;89(3):187-97
pubmed: 22687050
Rev Port Cardiol. 2016 Nov;35(11):601-616
pubmed: 27712930
Minerva Urol Nefrol. 2017 Jun;69(3):307-312
pubmed: 27768023
BMJ Open. 2017 Jul 10;7(7):e016028
pubmed: 28698338
Circ Heart Fail. 2010 May;3(3):451-8
pubmed: 20484195
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
J Clin Hypertens (Greenwich). 2016 May;18(5):456-67
pubmed: 26726000
Indian J Nephrol. 2016 Mar-Apr;26(2):125-30
pubmed: 27051137
Am J Blood Res. 2014 Sep 05;4(1):1-6
pubmed: 25232499
Kidney Int. 2017 Jan;91(1):196-203
pubmed: 28029431
J Am Coll Cardiol. 2018 Mar 20;71(11):1201-1203
pubmed: 29544602
Drug Des Devel Ther. 2016 Jan 29;10:465-81
pubmed: 26893541
Crit Care. 2014 Jul 01;18(4):R137
pubmed: 24985156
Kidney Int. 2011 Oct;80(8):806-21
pubmed: 21697815
J Am Coll Cardiol. 2016 Sep 27;68(13):1420-1431
pubmed: 27659464
Transl Pediatr. 2014 Oct;3(4):287-92
pubmed: 26835348
Circulation. 2013 Jul 16;128(3):281-308
pubmed: 23775258
J Cardiovasc Magn Reson. 2008 Sep 25;10:42
pubmed: 18817553
Adv Perit Dial. 1994;10:99-103
pubmed: 7999874
Ann N Y Acad Sci. 2005;1054:40-7
pubmed: 16339650
Blood Purif. 2014;37(4):271-85
pubmed: 25012891
Am J Med. 2005 Sep;118(9):957-67
pubmed: 16164878
Ann Hematol. 2019 May;98(5):1101-1110
pubmed: 30721337
Proc (Bayl Univ Med Cent). 2007 Jan;20(1):27-31
pubmed: 17256039
Am Heart J. 2010 Jan;159(1):68-74
pubmed: 20102869
J Am Soc Nephrol. 2012 Aug;23(8):1299-302
pubmed: 22677552
Blood Rev. 2010 Nov;24(6):239-44
pubmed: 20850917
Circulation. 1964 Nov;30:698-705
pubmed: 14226168
J Am Coll Cardiol. 2009 Mar 17;53(11):982-91
pubmed: 19281931
Minerva Anestesiol. 2015 Nov;81(11):1192-200
pubmed: 25479470
Electrolyte Blood Press. 2012 Dec;10(1):12-7
pubmed: 23508646
Clin Med Insights Cardiol. 2010 Dec 20;4:135-41
pubmed: 21234293
Curr Heart Fail Rep. 2011 Jun;8(2):99-105
pubmed: 21380936